Psilocybin, the active compound in ‘magic mushrooms’, is generating significant attention in mental health and medical communities, and many people want to understand its legal status before speaking with their doctor about it.
A 2026 executive order has accelerated federal research and FDA review of psychedelic therapies, but psilocybin remains a Schedule I controlled substance at the federal level. That distinction matters, and this article will clarify it in detail.
Below, we explain the current legal landscape, what the new policy changes actually mean, what psilocybin therapy looks like in clinical practice, and how Keta Medical Center would offer it if and when regulatory pathways allow.
The 2026 executive order on psychedelics: A quick overview
On April 18, 2026, President Trump signed an executive order titled Accelerating Medical Treatments for Serious Mental Illness. The order speeds up FDA review of promising psychedelic drugs, puts $50 million toward research, and makes it easier for eligible patients to try these treatments before they are fully approved.
It’s important to clarify what the executive order does not do. It does not legalize psilocybin, approve it for medical use, or change its Schedule I status.
It does, however, accelerate the federal research and review process. Final approval still requires completion of Phase 3 clinical trials and standard FDA evaluation.
Following the executive order, there has been significant discussion regarding the potential for Commissioner’s National Priority Vouchers to accelerate review timelines. While companies have applied for these vouchers—which could compress review timelines to one or two months—the granting of such vouchers remains subject to ongoing regulatory and political review, and their status is not yet confirmed.
So, is psilocybin legal?
At the federal level: no. Psilocybin is currently classified as a Schedule I controlled substance under the federal Controlled Substances Act, the most restrictive category, reserved for substances deemed to have no accepted medical use and high potential for abuse.
At the state level, the picture is more nuanced. Oregon and Colorado have legalized regulated psilocybin therapy programs for adults. In 2025, New Mexico also legalized a regulated market. Several other states have decriminalized personal possession or are actively advancing legislation. State laws vary significantly and continue to evolve.
There is one additional pathway: clinical trials. Psilocybin can be administered legally in the U.S. under FDA-supervised clinical trials. Patients enrolled in approved trials can access therapeutic psilocybin in a monitored medical setting, even in states where it’s otherwise prohibited.
When is psilocybin going to be legal?
There is no confirmed federal legalization date for psilocybin. However, the regulatory environment is evolving faster than at any point in recent history, and several developments are worth following closely.
For federal approval to occur, psilocybin must:
- Complete Phase 3 clinical trials demonstrating safety and efficacy
- Receive a positive FDA review
- Potentially be rescheduled by the DEA from Schedule I to a lower schedule
The 2026 executive order accelerates FDA review timelines but does not eliminate these requirements.
As of May 2026, two psilocybin programs, Compass Pathways’ COMP360 and the Usona Institute’s formulation, have received FDA priority vouchers, placing them at the front of the review queue. If Phase 3 data support approval, expedited review could significantly accelerate the timeline to market.
Patients in Oregon, Colorado, and New Mexico can access regulated psilocybin therapy now. Additional states are advancing legislation. Patients interested in current access may explore whether a licensed program exists in their state.
At Keta Medical Center, we are actively monitoring the regulatory landscape and preparing to offer psilocybin therapy as soon as approved pathways are available in New York and New Jersey.
What is psilocybin therapy, and who is it for?
Psilocybin therapy is a clinician-supervised, structured treatment that pairs a carefully dosed psilocybin experience with preparation sessions before and integration support afterward. It’s not a recreational experience: it takes place in a monitored medical setting, guided by trained clinicians who help patients process what arises during the session.
Current clinical research has examined psilocybin therapy as a potential treatment for a range of conditions, including:
- Treatment-resistant depression
- Major depressive disorder
- Post-traumatic stress disorder (PTSD)
- Generalized anxiety disorder
- End-of-life anxiety in patients with life-threatening illness
- Alcohol use disorder and other substance use disorders
A typical psilocybin therapy protocol involves one to three preparatory sessions with a therapist, a single supervised dosing session lasting four to six hours in a calm, carefully controlled environment, and one or more integration sessions afterward to help the patient make meaning of the experience.
Potential benefits observed in clinical settings include sustained reductions in depressive symptoms, improvements in emotional openness and psychological flexibility, and a reported sense of connectedness or perspective shift that outlasts the session itself.
Does Keta Medical Center offer psilocybin therapy?
Not yet. Psilocybin currently remains a Schedule I controlled substance federally, which means it cannot be administered outside of approved clinical trials in most states. Keta Medical Center operates within that regulatory framework and does not currently offer psilocybin therapy.
That said, we are closely following the evolving regulatory landscape and are preparing to integrate psilocybin-assisted therapy into our care model when approved pathways become available, and if the scientific evidence clearly shows that it is both safe and effective.
Our background in ketamine-assisted psychotherapy has given us direct experience with psychedelic-adjacent treatments in clinical settings: physician oversight, carefully managed therapeutic environments, patient preparation, and post-session support. These are the same pillars that define effective psilocybin therapy in research settings.
Ketamine therapy, which we offer today, works in many of the same ways as psilocybin in the brain and has strong clinical evidence for treatment-resistant depression and other mental health conditions. It may be an appropriate option while broader regulatory approvals are pending.
Interested in learning more about ketamine therapy and if it’s right for you?
Schedule a free phone consultation with our team to discuss your treatment options.
FAQ’s
Yes. Psilocybin is the primary psychoactive compound found in certain species of mushrooms, commonly referred to as 'magic mushrooms.' When ingested, it’s converted in the body to psilocin, which produces altered perception and shifts in mood and cognition.
Current evidence suggests psilocybin has low addiction potential. Unlike stimulants or opioids, it does not produce compulsive drug-seeking behavior in research settings and shows little to no physical dependence.
In supervised clinical settings, psilocybin is generally well-tolerated, but it’s not without risks. Common side effects include nausea, increased heart rate and blood pressure, headache, and temporary anxiety or emotional discomfort during the session.
Not currently. Because psilocybin is not FDA-approved as a prescription medication, it’s not eligible for standard insurance reimbursement. Even in Oregon and Colorado, where regulated programs exist, most patients pay out of pocket. If and when the FDA approves psilocybin for specific indications, coverage questions will depend on how it’s classified and prescribed, a process that will likely take additional years to resolve.
